Ernexa Therapeutics Inc.
13F holders, Q4 2025 (December 31)14holders
3new positions
3sold out
$1.20avg. 13F price*
At the end of Q4 2025, 14 institutions reported holding Ernexa Therapeutics Inc. in their 13F filings, unchanged from Q3 2025. 3 opened new positions and 3 sold out. The largest holders were Corient Private Wealth LP ($526K), Vanguard Group Inc. ($43K) and Geode Capital Management, LLC ($28K).
- Company
- Ernexa Therapeutics Inc.
- CUSIP
- 114082308
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $17K |
| Exits | 3 | $40K |
All 13F filers, Q3 2025 → Q4 2025: 41,969 shares bought and 36,199 shares sold, net +5,770 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Corient Private Wealth LP | 0.00% | No change | 438,092 | $526K |
| Vanguard Group Inc. | 0.00% | Add +222.3% | 35,922 | $43K |
| Geode Capital Management, LLC | 0.00% | Add +15.5% | 23,617 | $28K |
| HRT Financial LP | 0.00% | New | 12,625 | $15K |
| Sippican Capital Advisors | 0.01% | No change | 10,000 | $12K |
| BlackRock, Inc. | 0.00% | No change | 820 | $984 |
| Fortitude Family Office, LLC | 0.00% | New | 804 | $965 |
| UBS Group AG | 0.00% | New | 600 | $720 |
| Assetmark, Inc. | 0.00% | No change | 133 | $160 |
| Bank of America Corp. | 0.00% | Add +3.0% | 34 | $41 |
| Morgan Stanley | 0.00% | Reduce -61.0% | 30 | $36 |
| BNP Paribas Financial Markets | 0.00% | No change | 10 | $12 |
| Montag A & Associates Inc. | 0.00% | No change | 8 | $10 |
| Activest Wealth Management | 0.00% | No change | 3 | $4 |
"% of holder's portfolio" is ERNEXA THERAPEUTICS INC's weight in each manager's 13F, not the share of Ernexa Therapeutics Inc. the manager owns.